DBV Technologies peanut allergy drug fails key study
11 months, 23 days ago
WASHINGTON: DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.
Nasdaq-listed shares of the French drug…